Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate adjunctive therapy for partial onset seizures
NL-OMON34010Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carisbamate in epilepsy and Focal onset seizure (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percent reduction in partial onset seizure frequency, Responder rate and 1 more. Started Mar 2009; status: active, not recruiting.
02
Drugs
carisbamate
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on NL-OMON34010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34010.